People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

The medications approved by the Food and Drug Administration (FDA) for treating Huntington’s disease chorea are Xenazine (tetrabenazine), Ingrezza (velbenazine) and Austedo (deuterabenazine).

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

The US Food and Drug Administration (FDA) has approved deutetrabenazine extended-release tablets (Austedo XR, Teva), a new once-daily formulation of the drug for adults with tardive dyskinesia (TD) or ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA ® (valbenazine) capsules for the treatment of adults ...

Symptoms of ARF tend to present themselves 1-3 weeks after infection. A high index of suspicion for ARF must be maintained, especially because a single diagnostic tool does not exist. Thomas D. Jones ...